SENSEX NIFTY

Roche

Mar 03, 2017 at 11:26 | Source: CNBC-TV18
Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.
Feb 27, 2017 at 15:17 | Source: Moneycontrol.com
Oseltamivir Phosphate capsules also market by Roche under brand name Tamiflu is anti-viral pill used in the prevention and treatment of influenza virus infection. The estimated sales for Oseltamivir Phosphate capsules is $382 million as per IMS December 2016 figures.
Feb 22, 2017 at 20:38 | Source: PTI
The Delhi High Court today told Swiss pharma major Roche that it "cannot hang on to" breast cancer drug Trastuzumab, innovated by it, for the rest of its life after having enjoyed the fruits of its patent.
Feb 14, 2017 at 15:25 | Source: Moneycontrol.com
The revenue and profit growth for the company during the quarter was driven predominantly by the sales of Oseltamivir product or generic Tamiflu in the US market and includes profit sharing from our marketing partner, Natco said in a statement.
Jan 18, 2017 at 10:50 | Source: Reuters
Twenty-two companies, including Pfizer, Merck, Novartis, Roche, Sanofi and GlaxoSmithKline, will contribute funds and expertise to the project, which is backed by the World Bank.
Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Dec 27, 2016 at 09:59 | Source: Moneycontrol.com
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the USFDA for Tretinoin Capsules, 10 mg, the generic version of Vesanoid Capsules, 10 mg, of Hoffmann La Roche, Inc.
Dec 13, 2016 at 13:12 | Source: Moneycontrol.com
Shilpa Medicare has received an approval from the United States Food & Drug Administration (USFDA) (the Office of Bioequivalence) for Capecitabine Tablets USP, 150 mg and 500 mg to be bioequivalent and therapeutically equivalent to the reference listed drug product (RLD), Xeloda Tablets, 150 mg and 500 mg of Hoffmann-La Roche, Inc.
Jun 04, 2016 at 15:30 | Source: PTI
Global pharma major Mylan Inc, and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, incomparison to Roche's branded Herceptin used for treatment of cancer
Apr 26, 2016 at 22:08 | Source: PTI
The Delhi High Court has allowed pharma firms, Biocon Ltd and Mylan Pharmaceuticals Pvt Ltd, to continue with manufacture and marketing of their breast cancer drug under their brand names 'CANMAb' and 'HERTRAZ'.
Messages on Roche »

savera_patn
a

Platinum Member

41 Followers

Biocon  

http://t.in.com/e6Rv Mylan and partner Biocon cleared another hurdle with their version of Roche’s breast cancer med Herceptin, one of the biggest biosim targets in the market.

8.48 PM Mar 14th

savera_patn
a

Platinum Member

41 Followers

Biocon  

Remarkable deal struck by Mylan with patent holder Roche. They will instantly launch Trastuzumab in Europe/US post approval whereas others will have to do patent dance in US .

8.41 PM Mar 14th

koppik

Gold Member

11 Followers

Biocon  

Quoting the release: "In addition to eliminating any legal uncertainty over the launch of Mylan`s trastuzumab, the settlement eliminates further patent litigation expenses associated with Genentech and Roche." "Following this settlement and the recent acceptance of Mylan`s application for its

9.06 PM Mar 13th

koppik

Gold Member

11 Followers

Biocon  

Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin® Major boost for future of Biocon! http://newsroom.mylan.com/2017-03-13-Mylan-Announces-Global-Settlement-and-License-Agreements-with-Genentech-and-Roche-on-Herceptin-R

8.40 PM Mar 13th

pennystktra
der

New Member

2 Followers

Biocon  

The legal battle involving drugmaker Roche s breast cancer drug Trastuzumab took a significant turn on Friday with the Delhi High Court allowing drugmakers Biocon and Mylan to sell their version of the biosimilar drug for three treatment indications.

2.03 PM Mar 6th

Wire News

Platinum Member

725 Followers

News Now  

Swiss pharma major Roche cannot prima facie have a say against the sale and marketing of breast cancer medicines of drug firms Biocon and Mylan once the Drugs Controller General of India (DCGI) has approved it, Delhi High Court said today.

7.06 PM Mar 2nd

andyin

New Member

6 Followers

Biocon  

Market is reacting to Roche clearing Perjata study which may have impact on Trastuzumab sales as Perjata has superior survival rates. But the big question is how many people can afford it. So negligible to nil impact to in most of the markets. In US and Europe may be marginal impact. Anyway all

3.50 PM Mar 2nd

Wire News

Platinum Member

725 Followers

News Now  

The Delhi High Court today told Swiss pharma major Roche that it "cannot hang on to" breast cancer drug Trastuzumab, innovated by it, for the rest of its life after having enjoyed the fruits of its patent.

8.38 PM Feb 22nd

dhruvfun

New Member

3 Followers

Biocon  

i can`t believe how people are not able to understand what biocon is !! biocon is a world class biopharma firm, that has world class talent pool of scientists!! its trastuzumab biosimilar is showing much better results than herceptin which generates 40,000 crores alone in revenue for roche!! it

10.07 AM Jan 5th

businesswor
ld2016

New Member

1 Followers

index  

The approved product is a generic version of Vesanoid capsules, 10 mg, of Hoffmann La Roche, Inc. (which is no longer being marketed in the US), the company added.

5.16 PM Dec 28th 2016

News across the web »
Mar 28, 2017 at 00:15 | Source: FirstPost
Mar 27, 2017 at 21:46 | Source: FirstPost
Follow us on
Available On